Two-year Follow-Up Data on the Efficacy and Safety of KN026, a HER2-targeted Bispecific Antibody Combined with Docetaxel As First-Line Treatment for HER2-positive Recurrent/metastatic Breast Cancer
ANNALS OF ONCOLOGY(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined